Business Of Biotech podkast

Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.

0:00
45:51
Do tyłu o 15 sekund
Do przodu o 15 sekund

The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial.  Bit.bio is exemplary of this new breed. Its CEO, Dr. Mark Kotter doesn’t pull any punches when addressing the complexity involved in building out the company’s capabilities. At the discovery stage alone, bit.bio has hired – and integrated – stem cell biologists, synthetic biologists, genetic engineering experts, cellular biologists, sequencing experts, data scientists, bioinformatics pros, and machine learning experts. 
On this episode of the Business of Biotech, recorded in San Francisco during JPM Week, we catch up with Dr. Kotter on the work bit.bio is doing, how it’s doing it, and how he and his leadership team are recruiting and retaining a new breed of biotech talent to sustain the effort. Let’s give it a listen. 

You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Więcej odcinków z kanału "Business Of Biotech"